title: Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
authors.affiliation: Department of Oncology, Herlev University Hospital , Herlev , Denmark.
authors.forename: Malgorzata K
authors.initials: MK
authors.lastname: Tuxen
authors.forename: Soeren
authors.initials: S
authors.lastname: Cold
authors.forename: Ulla B
authors.initials: UB
authors.lastname: Tange
authors.forename: Eva
authors.initials: E
authors.lastname: Balslev
authors.forename: Dorte L
authors.initials: DL
authors.lastname: Nielsen
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D018401:Sample Size; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide; D000077143:Docetaxel; D004317:Doxorubicin; D011092:Polyethylene Glycols; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D043823:Taxoids; D000068878:Trastuzumab; C506643:liposomal doxorubicin